DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A Comparison of Dapsone and Trimethoprim-Sulfamethoxazole in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS

Information source: NIH AIDS Clinical Trials Information Service
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Pneumonia, Pneumocystis Carinii; HIV Infections

Intervention: Trimethoprim (Drug); Sulfamethoxazole (Drug); Dapsone (Drug)

Phase: N/A

Status: Completed

Sponsored by: Jacobus Pharmaceutical

Summary

Evaluate the effectiveness rate of dapsone plus trimethoprim as a therapy for the first episode of Pneumocystis carinii pneumonia (PCP) in AIDS patients. Compare the rates and

severity of adverse effects using dapsone versus trimethoprim - sulfamethoxazole (TMP /

PurposeX). Establish relative toxicities with regard to suitability for outpatient treatment.

Clinical Details

Official title: Randomized Prospective Study of Dapsone Versus Trimethoprim-Sulfamethoxazole in the Treatment of First Episode Pneumocystis Carinii Pneumonia in AIDS Patients

Study design: Allocation: Randomized, Primary Purpose: Treatment

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Exclusion Criteria Concurrent Medication: Excluded:

- Requirement for other medications found to be effective in the treatment of

Pneumocystis carinii pneumonia (PCP) (i. e., DFMO, pyrimethamine, and sulfadiazine). Patients with the following are excluded:

- History of allergic reaction to dapsone.

- Requirement for other medications found to be effective in the treatment of

Pneumocystis carinii pneumonia (PCP) (i. e., DFMO, pyrimethamine, and sulfadiazine).

- Patients subsequently found to be glucose-6-phosphate dehydrogenase (G6PD) positive

will be withdrawn from the study and treated with another regimen. Prior Medication: Excluded:

- Requirement for other medications found to be effective in the treatment of

Pneumocystis carinii pneumonia (PCP) (i. e., DFMO, pyrimethamine, and sulfadiazine). Patients who are glucose-6-phosphate dehydrogenase (G6PD) positive will be withdrawn from the study and treated with another regimen. Hospitalized patients with first episode of Pneumocystis carinii pneumonia (PCP) documented by GIEMSA or methenamine stain.

- Patients must:

- Be willing and able to give informed consent.

- Be expected to survive 1 week without therapy.

- Have less than 48 hours of treatment for Pneumocystis carinii pneumonia (PCP) for

this episode.

Locations and Contacts

Jacobus Pharmaceutical Co, Princeton, New Jersey 08540, United States
Additional Information


Last updated: June 23, 2005

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017